Published online Jul 6, 2019. doi: 10.12998/wjcc.v7.i13.1703
Peer-review started: February 11, 2019
First decision: April 18, 2019
Revised: April 22, 2019
Accepted: May 3, 2019
Article in press: May 3, 2019
Published online: July 6, 2019
Processing time: 154 Days and 1.8 Hours
Synchronous multiple primary cancers (SMPC) mean two or more malignant tumors occurring simultaneously and with different origins no matter what types they are or where they are located. The carcinogenesis of SMPC often involves variations of some specific genes. However, the correlation between CDH1 mutations and synchronous multiple primary gastrointestinal cancers is largely unknown.
A 62-year-old woman had sustained abdominal pain for one week and visited our hospital. Gastrointestinal endoscopy revealed multiple small polypoid lesions in both the stomach and colorectum. Computed tomography and laboratory results were within normal limits. Pathological evaluation confirmed signet ring cell carcinoma without obvious metastatic evidence. Malignant cells showed negativity for E-cadherin and positivity for β-catenin in the cytoplasm and nucleus. DNA sequencing performed on paraffin-embedded tissue revealed two exactly coincident alterations in CDH1, C.57T>G and C.1418A>T.
This case suggests that the combination of CDH1 mutations and WNT/β-catenin signaling activation contributes to the carcinogenesis of gastrointestinal SMPC.
Core tip: A 62-year-old woman was admitted with abdominal pain for one week. Gastrointestinal endoscopy revealed multiple small polypoid lesions in both the stomach and colorectum. A diagnosis of primary signet ring cell carcinoma was established based on the combination of pathological and imageologic evaluations. E-cadherin expression was downregulated in the malignant cells, where β-catenin was aberrantly translocated to the cytoplasm and nucleus. DNA sequencing indicated C.57T>G and C.1418A>T in CDH1, suggesting the important role of CDH1 mutations in the pathogenesis of synchronous multiple primary gastrointestinal cancers.